Peptide half-life determines how long a compound remains active in the body and directly informs optimal injection timing and frequency. A peptide with a 10-minute half-life behaves very differently from one with a 6-day half-life — both in how to time injections for maximum effect and in how frequently re-dosing is needed. This reference covers half-lives for all commonly researched peptides and explains the practical dosing implications of each.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
For subcutaneous peptides, food co-ingestion is generally irrelevant — SubQ absorption is not meaningfully affected by meal timing. For oral peptides (MK-677, oral BPC-157), food may slow absorption and reduce peak concentration, though for compounds taken chronically, this often doesn't matter significantly. Specific compounds (GHRP-6) work best fasted to avoid insulin-mediated blunting of GH response.
Why Half-Life Matters for Peptides
Half-life is the time required for blood plasma concentration of a compound to fall to 50% of its peak value. After approximately 4–5 half-lives, a compound has cleared to near-negligible concentrations (<5% of peak). For research peptides injected subcutaneously, the "effective duration" of action is typically 4–6 half-lives from peak absorption, which itself occurs 30–90 minutes post-injection depending on the peptide.
Practically: a peptide with a 30-minute half-life injected subcutaneously produces effects for approximately 2–3 hours. A peptide with a 2-hour half-life produces effects for 8–10 hours. One with a 6-day half-life (CJC-1295 with DAC) requires weekly rather than daily injection. Understanding this determines whether single-dose daily is appropriate, split dosing is needed, and what time of day administration is optimal for the intended mechanism.
Half-Life and Timing for GH Secretagogues
GH secretagogues are particularly timing-sensitive. Their value derives from stimulating pulsatile GH release — ideally coinciding with the natural nocturnal GH surge that occurs in the first 1–2 hours of deep sleep. For short-half-life GHRHs and GHRPs (Sermorelin 10–20 min, GHRP-2/GHRP-6 ~30 min, Ipamorelin ~2 hours), pre-sleep injection 30 minutes before lights-out is standard practice to time the pulsatile GH release during peak natural GH secretion. CJC-1295 without DAC (30–45 minutes half-life) also requires pre-sleep timing. CJC-1295 with DAC (6–8 days) is injected once weekly and does not require timing to sleep.
Implications for Split Dosing
Some compounds benefit from split dosing to maintain more consistent blood levels. BPC-157 at twice-daily dosing (morning and pre-sleep) maintains more continuous tissue exposure than single daily dosing — relevant for chronic injury treatment where sustained tissue-level peptide availability is beneficial. Selank and Semax with 2–4 hour effective durations are naturally suited to morning dosing for work performance, with optional afternoon re-dose for extended cognitive demands. MK-677 (ghrelin mimetic, oral, 24-hour half-life) is typically once-daily, most often pre-sleep to leverage nocturnal GH pulse enhancement.
Peptide Half-Life Reference
| Peptide | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| BPC-157 | ~30–60 min | SubQ/IM | Once or twice daily | Morning + pre-sleep split is common |
| TB-500 | ~2–3 days | SubQ | 2–3× per week | Long half-life; no daily dosing needed |
| Sermorelin | 10–20 min | SubQ | Once daily — pre-sleep | Strictly pre-sleep for GH pulse |
| CJC-1295 (no DAC) | 30–45 min | SubQ | Once daily — pre-sleep | Short active window; pre-sleep critical |
| CJC-1295 (with DAC) | 6–8 days | SubQ | Once weekly | No timing requirement |
| Ipamorelin | ~2 hours | SubQ | Once or twice daily | Pre-sleep preferred; morning optional |
| GHRP-2 / GHRP-6 | ~30 min | SubQ | 2–3× daily | Fasting important for GHRP-6 hunger effect |
| MK-677 | ~24 hours (oral) | Oral | Once daily — pre-sleep | Pre-sleep for GH pulse; oral convenience |
| Semax | ~2–4 hours (IN) | Intranasal | Once or twice daily | Morning dose standard; afternoon optional |
| Selank | ~1–3 hours (IN) | Intranasal | Once or twice daily | As-needed; pre-task dosing effective |
| Epithalon | ~1 hour | SubQ/IV | Once daily (during course) | Morning or evening dosing both used |
| GHK-Cu | ~30–60 min | SubQ or topical | Once daily (SubQ) | Topical provides different kinetics |
| IGF-1 LR3 | 20–30 hours | SubQ | Once daily or every other day | Long half-life; spacing important |
| PT-141 | ~2.7 hours | SubQ | As-needed, pre-activity | Administer 45–90 min before activity |
| Semaglutide | ~7 days | SubQ | Once weekly | Consistent day each week recommended |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Not necessarily — it depends on the desired pharmacological profile. For GH secretagogues, short half-life preserves physiological pulsatility which is actually considered an advantage over long-acting versions for chronic use. For TGF-β-driven tissue repair peptides like BPC-157, longer effective duration may be advantageous. Half-life is a pharmacokinetic property, not a quality metric.
For subcutaneous peptides, food co-ingestion is generally irrelevant — SubQ absorption is not meaningfully affected by meal timing. For oral peptides (MK-677, oral BPC-157), food may slow absorption and reduce peak concentration, though for compounds taken chronically, this often doesn't matter significantly. Specific compounds (GHRP-6) work best fasted to avoid insulin-mediated blunting of GH response.
CJC-1295 with DAC uses a Drug Affinity Complex — a reactive maleimide group that covalently binds to albumin (the most abundant blood protein) after injection. Once bound to albumin, the peptide shares albumin's 19-day half-life rather than being rapidly degraded. This allows once-weekly injection but creates continuous GHRH receptor activation without pulsatility, which some researchers consider a disadvantage.